- IPO / Stock
- Went Public on Oct 1, 2013 / NASDAQ:FATE
- Total Equity Funding
- $65.19M in 4 Rounds from 5 Investors
- La Jolla, CA
- Fate Therapeutics is a stem cell and developmental biology research company using biological mechanisms to develop stem cell therapeutics.
- Michael Rudnicki, Len Zon, Randall Moon, Rudolf Jaenisch, Phillip Beachy, David Scadden, Alex Rives, Sheng Ding
Founded in 2007 on the leading stem cell and developmental biology research, Fate Therapeutics is using the fundamental biological mechanisms that guide cell fate to develop stem cell therapeutics. The company has brought together the foremost scientists from the nationâ€™s research hotbeds (Boston, San Francisco, San Diego and Seattle) who have demonstrated the potential to create and modulate stem cells to restore health.
The backstory is that while others were working towards therapies based on transplanting stem cell-derived cells into patients, Randall Moon (HHMI and University of Washington) and Alex Rives (Arch Venture Capitol) envisioned a different approach to develop regenerative therapies. The concept, based on data from hematopoietic progenitor cells, was that one could modulate the properties of stem cells in vivo using small molecules or biologics. They presented this idea to Arch Venture Capitol in Seattle, which launched the company, soon to be joined by other investors.
Funding Rounds (7) - $96.48MUpdate
Current Team (13)Update
Board Members and Advisors (4)Update
|Aug 22, 2016||SEC - UNITED STATES SECURITIES AND EXCHANGE COMMISSION|
|Aug 4, 2016||Business Wire - Juno Therapeutics Reports Second Quarter 2016 Financial Results|
|Jun 17, 2016||PRNewswire All - Global Tuberculosis Pipeline 2016 Market Report on 64 Companies|
|Jun 17, 2016||PRNewswire UK All - Global Tuberculosis Pipeline 2016 Market Report on 64 Companies|
|Mar 23, 2016||PRNewswire UK All - Tissue Engineering Market Worth $11.5 Billion By 2022: Grand View Research, Inc.|
|Jan 18, 2016||LifeSciVC | Recovering scientist turned early stage VC - The Entrepreneurial Diaspora Enabled By Biotech M&A|
|Dec 10, 2015||Business Wire - Research and Markets: Lysosomal Storage Disorder Pipeline Study 2015 - 13 Companies & 24 Drug Profiles|
|Dec 8, 2015||PRNewswire All - Stem Cell Technologies and Applications Market Report 2016-2026|
3535 General Atomics Court
San Diego, CA 92121
10931 North Torrey Pines Road
La Jolla, CA 92037